Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Hepatocellular 57Stomach Neoplasms 45Carcinoma, Non-Small-Cell Lung 36Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Rectal Neoplasms 11Lung Neoplasms 11Esophageal Neoplasms 11Nasopharyngeal Carcinoma 10Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Cholangiocarcinoma 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Triple Negative Breast Neoplasms 4Recurrence 4Liver Neoplasms 4Endometrial Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Solid Tumor 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3

Interventions

Cisplatin 4sintilimab 1Radiation Dose Hypofractionation 1Radiation 1Irinotecan 1Immunotherapy 1Brachytherapy 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Locally Advanced Cervical Carcinoma × sintilimab × Clear all
NCT06391190 2024-04-30

Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer

RenJi Hospital

Phase 1/2 Recruiting
20 enrolled
Gynecologic

Locally Advanced Cervical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡